Spero Therapeutics (SPRO) Interest & Investment Income (2018 - 2026)
Spero Therapeutics' (SPRO) quarterly Interest & Investment Income came in at $336000.0 in Q1 2026, down 61.11% YoY from $864000.0 in Q1 2025, and down 10.64% on a QoQ basis from $376000.0 in Q4 2025.
Spero Therapeutics (SPRO) Interest & Investment Income (2018 - 2026) Analysis & Trends
Spero Therapeutics (SPRO) has 9 years of Interest & Investment Income data on file, last reported at $336000.0 in Q1 2026.
- Quarterly Interest & Investment Income fell 61.11% year-over-year to $336000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 million (down 53.56% YoY) and the FY2025 annual result came in at $2.5 million, down 46.95% from the prior year.
- Interest & Investment Income fell to $336000.0 in Q1 2026, from $376000.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $1.3 million in Q1 2024 to a low of $6000.0 in Q2 2022.
- A 5-year average of $769625.0 and a median of $907000.0 in 2023 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2022 — Interest & Investment Income plunged 92.68% — and 2023, when it soared 16266.67%.
- Tracing SPRO's Interest & Investment Income over 5 years: stood at $715000.0 in 2022, then jumped by 45.87% to $1.0 million in 2023, then dropped by 1.44% to $1.0 million in 2024, then tumbled by 63.42% to $376000.0 in 2025, then dropped by 10.64% to $336000.0 in 2026.
- The last three Interest & Investment Income figures came in at $336000.0 (Q1 2026), $376000.0 (Q4 2025), and $532000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Spero Therapeutics | 70.72 Mn | 19.95 Mn | - | 377,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 377,000.00 |
| Mar 31, 2026 | 336,000.00 |
| Dec 31, 2025 | 376,000.00 |
| Sep 30, 2025 | 532,000.00 |
| Jun 30, 2025 | 740,000.00 |
| Mar 31, 2025 | 864,000.00 |
| Dec 31, 2024 | 1.03 Mn |
| Sep 30, 2024 | 1.18 Mn |
| Jun 30, 2024 | 1.20 Mn |
| Mar 31, 2024 | 1.33 Mn |
| Dec 31, 2023 | 1.04 Mn |
| Sep 30, 2023 | 950,000.00 |
| Jun 30, 2023 | 982,000.00 |
| Mar 31, 2023 | 963,000.00 |
| Dec 31, 2022 | 715,000.00 |
| Jun 30, 2022 | 6,000.00 |
| Mar 31, 2022 | 72,000.00 |
| Jun 30, 2021 | 82,000.00 |
| Mar 31, 2021 | 4,000.00 |
| Dec 31, 2020 | 416,000.00 |